Grufity logoGrufity logo
StocksFundsSearch Filings

Axonics Modulation Technologies Inc Stock Research

AXNX

48.54USD-1.11(-2.24%)Market Closed

Market Summary

USD48.54-1.11
Market Closed
-2.24%

AXNX Alerts

AXNX Stock Price

AXNX RSI Chart

AXNX Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-52.56

Price/Sales (Trailing)

8.22

EV/EBITDA

-59.11

Price/Free Cashflow

274.81

AXNX Price/Sales (Trailing)

AXNX Profitability

EBT Margin

-22.77%

Return on Equity

-10.47%

Return on Assets

-9.05%

Free Cashflow Yield

0.36%

AXNX Fundamentals

AXNX Revenue

Revenue (TTM)

295.9M

Revenue Y/Y

45.91%

Revenue Q/Q

-17.77%

AXNX Earnings

Earnings (TTM)

-46.3M

Earnings Y/Y

59.2%

Earnings Q/Q

-1.5K%

Price Action

52 Week Range

46.5779.92
(Low)(High)

Last 7 days

-3.6%

Last 30 days

-15.5%

Last 90 days

-15.4%

Trailing 12 Months

-3.0%

AXNX Financial Health

Current Ratio

7.13

Debt/Equity

2e-4

Debt/Cashflow

-181.46

AXNX Investor Care

Shares Dilution (1Y)

6.61%

Diluted EPS (TTM)

-0.97

Peers (Alternatives to Axonics Modulation Tech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
110.8B
19.0B
-8.78% 16.43%
46.98
6.01
8.73% 30.37%
107.5B
6.4B
4.05% 37.44%
81.96
16.72
8.89% -20.19%
74.1B
13.0B
-0.08% 27.20%
106.12
5.84
7.26% -32.95%
71.3B
18.8B
-6.73% -3.13%
44.09
3.79
-1.96% -15.83%
49.7B
5.5B
-6.18% -16.80%
33.38
9.03
2.68% -3.23%
MID-CAP
7.2T
557.2M
-1.64% 66.40%
82.2K
16.8K
86.42% 730.06%
11.7B
884.6M
7.85% 115.97%
1.8K
13.2
13.08% 200.12%
5.9B
1.1B
-8.20% -19.98%
34.14
5.75
11.20% 53.04%
3.6B
430.0M
-11.89% -12.63%
-34.73
8.45
26.13% 15.73%
1.7B
794.7M
-29.15% -60.56%
-8.43
2.16
7.73% -3556.34%
SMALL-CAP
1.6B
389.0M
-3.76% 82.19%
-10.63
4.18
44.08% 6.96%
1.2B
150.7M
-30.80% 0.49%
-21.65
7.87
40.31% 1.80%
1.1B
814.3M
-20.14% -16.22%
24.47
1.34
6.96% 121.89%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for Axonics Modulation Tech

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue8.1%295,932,000273,702,000240,919,000217,448,000194,337,000
Gross Profit9.7%216,923,000197,665,000170,089,000150,023,000128,561,000
Operating Expenses3.8%272,702,000262,611,000249,106,000229,167,000202,286,000
  S&GA Expenses6.1%165,610,000156,019,000143,533,000131,894,000117,924,000
  R&D Expenses-9.2%31,230,00034,410,00036,489,00037,201,00039,164,000
EBITDA26.3%-50,594,000-68,627,000-68,807,000-66,975,000-
EBITDA Margin35.1%-0.18-0.28-0.32-0.34-
Earnings Before Taxes22.0%-48,592,000-62,316,000-80,112,000-80,062,000-80,006,000
EBT Margin31.5%-0.23-0.33-0.37-0.41-
Interest Expenses-100.0%0.001,0001,0002,0002,009,000
Net Income22.5%-46,278,000-59,698,000-75,530,000-76,528,000-80,233,000
Net Income Margin30.4%-0.22-0.31-0.35-0.41-
Free Cahsflow106.1%968,000-15,910,000-22,472,000-33,319,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets1.0%666659632514526
  Current Assets1.0%470465449313307
    Cash Equivalents0.5%240239241203213
  Inventory18.5%66.0056.0058.0058.0062.00
  Net PPE3.2%7.007.007.007.007.00
  Goodwill2.3%97.0094.0087.0095.00103
Liabilities-0.1%89.0089.0083.0076.0062.00
  Current Liabilities1.4%66.0065.0061.0030.0026.00
Shareholder's Equity1.1%577570550438463
  Retained Earnings-2.5%-383-374-374-358-337
  Additional Paid-In Capital1.3%982970961821812
Accumulated Depreciation8.0%7.007.006.00--
Shares Outstanding1.1%50.0050.0049.0047.0047.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations262.8%12.003.00-12.94-19.78-30.89
  Share Based Compensation11.2%36.0032.0030.0029.0027.00
Cashflow From Investing0.8%-119-120-111-12.69-2.43
Cashflow From Financing0.4%1341341344.00116

Risks for AXNX

What is the probability of a big loss on AXNX?

75.1%


Probability that Axonics Modulation Tech stock will be more than 20% underwater in next one year

56.4%


Probability that Axonics Modulation Tech stock will be more than 30% underwater in next one year.

44.0%


Probability that Axonics Modulation Tech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AXNX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Axonics Modulation Tech was unfortunately bought at previous high price.

Drawdowns

Returns for AXNX

Cumulative Returns on AXNX

8.5%


3-Year Cumulative Returns

Which funds bought or sold AXNX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
ROYCE & ASSOCIATES LP
reduced
-31.76
-2,150,570
3,164,480
0.03%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-37.00
-14,875,900
18,160,100
0.01%
2023-05-22
PUTNAM INVESTMENTS LLC
added
0.33
-1,009,090
7,090,670
0.01%
2023-05-18
JPMORGAN CHASE & CO
added
9.68
-1,029,940
22,928,100
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-30.19
-2,888,000
4,500,000
0.01%
2023-05-17
Thrivent Financial for Lutherans
added
2.19
-1,501,000
12,340,000
0.03%
2023-05-17
Advisory Services Network, LLC
unchanged
-
-2,017
13,804
-%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
added
18.87
41,214
787,878
0.01%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
125
587,551
1,197,160
-%
2023-05-16
Rockefeller Capital Management L.P.
added
41.04
39,000
208,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying AXNX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own AXNX
No. of Funds

Axonics Modulation Tech News

Benzinga
Axonics Modulation Tech Earnings Preview - Axonics (NASDAQ ....
Benzinga,
2 months ago
Investor's Business Daily

Schedule 13G FIlings of Axonics Modulation Tech

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 10, 2023
vanguard group inc
10.28%
5,092,888
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.82%
4,863,283
SC 13G/A
Jan 31, 2023
blackrock inc.
7.3%
3,630,843
SC 13G/A
Jun 06, 2022
cooperatieve gilde healthcare iv u.a.
0%
0
SC 13G/A
Feb 14, 2022
credit suisse ag/
4.90%
2,273,198
SC 13G/A
Feb 09, 2022
vanguard group inc
6.27%
2,902,696
SC 13G
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 03, 2022
blackrock inc.
7.6%
3,525,549
SC 13G/A
Apr 08, 2021
alfred e. mann foundation for scientific research
4.0%
1,602,970
SC 13G/A

AXNX Fair Value

Recent SEC filings of Axonics Modulation Tech

View All Filings
Date Filed Form Type Document
May 18, 2023
424B5
Prospectus Filed
May 18, 2023
8-K
Current Report
May 05, 2023
S-3ASR
S-3ASR
May 02, 2023
10-Q
Quarterly Report
May 01, 2023
8-K
Current Report
May 01, 2023
DEF 14A
DEF 14A
Apr 25, 2023
4
Insider Trading
Apr 24, 2023
4
Insider Trading
Apr 20, 2023
144
Notice of Insider Sale Intent
Apr 06, 2023
8-K
Current Report

Latest Insider Trading transactions for AXNX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-04-21
Dearen Danny L.
sold
-1,204,140
60.2069
-20,000
president & cfo
2023-04-21
Dearen Danny L.
acquired
187,422
14.19
13,208
president & cfo
2023-04-20
Dearen Danny L.
acquired
28,394
14.19
2,001
president & cfo
2023-04-20
Dearen Danny L.
sold
-120,073
60.0063
-2,001
president & cfo
2023-03-31
Dearen Danny L.
sold
-829,103
55.2735
-15,000
president & cfo
2023-03-31
Dearen Danny L.
acquired
240,031
16.0021
15,000
president & cfo
2023-02-21
Sama Rinda
sold
-191,750
56.53
-3,392
chief operating officer
2023-02-21
Sama Rinda
sold
-1,121,410
56.2705
-19,929
chief operating officer
2023-02-01
Ford Alfred J Jr
sold
-225,750
60.9311
-3,705
chief commercial officer
2023-02-01
Dearen Danny L.
sold
-197,782
60.9311
-3,246
president & cfo

1–10 of 50

Raymond W. Cohen
520
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Income Statement

2023-03-31
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]  
Net revenue$ 70,650$ 48,420
Cost of goods sold18,15015,178
Gross profit52,50033,242
Operating expenses  
Research and development8,05611,236
General and administrative12,16810,013
Sales and marketing42,65433,063
Amortization of intangible assets2,2222,463
Acquisition-related costs1,7660
Total operating expenses66,86656,775
Loss from operations(14,366)(23,533)
Other income (expense)  
Interest and other income3,62843
Interest and other expense683(289)
Other income (expense), net4,311(246)
Loss before income tax benefit(10,055)(23,779)
Income tax benefit(807)(1,111)
Net loss(9,248)(22,668)
Foreign currency translation adjustment3,071(4,920)
Comprehensive loss$ (6,177)$ (27,588)
Net loss per share, basic (in USD per share)$ (0.19)$ (0.50)
Net loss per share, diluted (in USD per share)$ (0.19)$ (0.50)
Weighted-average shares used to compute basic net loss per share (in shares)48,579,08445,139,038
Weighted-average shares used to compute diluted net loss per share (in shares)48,579,08445,139,038

AXNX Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 240,105$ 238,846
Short-term investments116,957118,365
Accounts receivable, net of allowance for credit losses of $322 and $321 at March 31, 2023 and December 31, 2022, respectively40,20044,817
Inventory, net66,06755,765
Prepaid expenses and other current assets6,3427,282
Total current assets469,671465,075
Property and equipment, net7,0176,798
Intangible assets, net85,88886,253
Other assets6,5346,813
Goodwill96,58194,414
Total assets665,691659,353
Current liabilities  
Accounts payable14,7379,070
Accrued liabilities6,6406,520
Accrued compensation and benefits8,83615,495
Operating lease liability, current portion1,5571,562
Other current liabilities34,40032,600
Total current liabilities66,17065,247
Operating lease liability, net of current portion7,1787,555
Deferred tax liabilities, net15,73716,412
Total liabilities89,08589,214
Commitments and contingencies (Note 3)
Stockholders’ equity  
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2023 and December 31, 202200
Common stock, par value $0.0001, 75,000,000 shares authorized at March 31, 2023 and December 31, 2022; 50,110,667 and 49,546,727 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively55
Additional paid-in capital982,189969,545
Accumulated deficit(383,512)(374,264)
Accumulated other comprehensive loss(22,076)(25,147)
Total stockholders’ equity576,606570,139
Total liabilities and stockholders’ equity$ 665,691$ 659,353